Black Diamond Therapeutics, Inc.
NASDAQ Global SelectTotal Valuation
Black Diamond Therapeutics, Inc. carries a market capitalization of 115.75M, placing it among publicly traded companies globally. Its enterprise value stands at 12.74M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 115.75M |
| Enterprise Value | 12.74M |
Share Statistics
Black Diamond Therapeutics, Inc. currently has 57.45M shares outstanding.
| Shares Outstanding | 57.45M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Black Diamond Therapeutics, Inc. trades at a trailing price-to-earnings ratio of 16.18.
| PE Ratio | 16.18 |
| PS Ratio | N/A |
| PB Ratio | 1.11 |
| P/TBV Ratio | 1.11 |
| P/FCF Ratio | -3.22 |
| P/OCF Ratio | -3.22 |
Enterprise Valuation
On an enterprise value basis, Black Diamond Therapeutics, Inc. trades at an EV/EBITDA multiple of 9.63 and an EV/FCF ratio of 5.66.
| EV / Sales | N/A |
| EV / EBITDA | 9.63 |
| EV / EBIT | 9.89 |
| EV / FCF | 5.66 |
Financial Position
Black Diamond Therapeutics, Inc. maintains a current ratio of 7.28, meaning it holds 7.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 7.28 |
| Quick Ratio | 6.98 |
| Debt / Equity | 17.66 |
| Debt / EBITDA | -0.38 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -37.21 |
| Return on Assets (ROA) | -29.21 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Black Diamond Therapeutics, Inc.'s stock has declined approximately -26.81159% over the past 52 weeks. The 50-day moving average sits at 1.84, while the 200-day moving average is 2.54.
| Beta (5Y) | N/A |
| 52-Week Price Change | -26.81159% |
| 50-Day Moving Average | 1.84 |
| 200-Day Moving Average | 2.54 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -44.35M, while operating income came in at -44.56M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -44.56M |
| Pretax Income | -42.55M |
| Net Income | -42.55M |
| EBITDA | -44.35M |
| EBIT | -44.56M |
| Earnings Per Share (EPS) | -0.74 |
Balance Sheet
Black Diamond Therapeutics, Inc. holds 110.51M in cash and equivalents against 16.97M in total debt, resulting in a net debt position of -19.19M. Total book value stands at 96.09M, with working capital of 99.55M providing operational flexibility.
| Cash & Cash Equivalents | 110.51M |
| Total Debt | 16.97M |
| Net Debt | -19.19M |
| Equity (Book Value) | 96.09M |
| Book Value Per Share | 1.67 |
| Working Capital | 99.55M |
Cash Flow
Black Diamond Therapeutics, Inc. produced -32.84M in operating cash flow over the past twelve months.
| Operating Cash Flow | -32.84M |
| Capital Expenditures | N/A |
| Free Cash Flow | -32.84M |
| FCF Per Share | -0.57 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 0.03 |
| FCF Yield | -31.06 |
Scores
Black Diamond Therapeutics, Inc. posts an Altman Z-Score of -3.43, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -3.43 |